Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (84.1%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies, etc. Moreover, Sanofi-Aventis markets OTC products and generic drugs;
- human vaccines (15.9%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas.
At the end of 2019, the group had 81 production sites throughout the world.
Net sales are distributed geographically as follows: Europe (24.5%), United States (35.3%), Asia (12.2%), Latin America (7.6%), Africa and Middle East (6.4%) and other (14%).
Number of employees : 100 409 people.
2018 2019 Delta EUR (in Million) % EUR (in Million) % Pharmaceuticals 24,685 71.6% 25,708 71.2% +4.14% Vaccines 5,118 14.9% 5,731 15.9% +11.98% Consumer Healthcare 4,660 13.5% 4,687 13% +0.58%
2019 EUR (in Million) % United States 12,756 35.3% Europe 6,591 18.2% Asia 4,393 12.2% Latin America 2,734 7.6% Africa and Middle East 2,307 6.4% France 2,261 6.3% Japan 1,908 5.3% Eurasia 1,312 3.6% Rest of the World 1,247 3.5% South Korea 449.00 1.2%
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
1
1,256,192,074
1,116,927,806
88.9% 2,590,000
0.2% 88.9%
Shareholders Sanofi (FR0000120578) Sanofi (US)
Name Equities % L'Oréal S.A. 118,227,307
9.39% The Vanguard Group, Inc. 33,464,092
2.66% Norges Bank Investment Management 26,690,482
2.12% Fidelity Management & Research Co. LLC 22,508,744
1.79% Plan d'Epargne Entreprise Sanofi Synthelabo 20,371,851
1.62% Lyxor International Asset Management SAS 15,088,524
1.20% Dodge & Cox 14,552,709
1.16% Amundi Asset Management SA (Investment Management) 13,869,395
1.10% FIL Investment Advisors (UK) Ltd. 10,603,841
0.84% BNP Paribas Asset Management France SAS 10,486,571
0.83%
Name Equities % Dodge & Cox 39,372,933
1.56% Fisher Asset Management LLC 18,624,240
0.74% Fidelity Management & Research Co. LLC 13,288,428
0.53% Marsico Capital Management LLC 10,211,978
0.41% Winslow Capital Management LLC 9,255,696
0.37% York Capital Management Global Advisors LLC 8,753,796
0.35% BlackRock Investment Management LLC 8,300,088
0.33% Montag & Caldwell LLC 7,303,272
0.29% Invesco Advisers, Inc. 6,584,977
0.26% Managed Account Advisors LLC 5,597,262
0.22%
Name Equities % Valuation
Sanofi India Limited (500674) 13,909,587 60.4% 1,502,261,685 USD Sanofi (SAN) 3,101,336 0.25% 279,506,201 USD Regeneron Pharmaceuticals (REGN) 279,766 0.27% 152,069,607 USD Inozyme Pharma, Inc. (INZY) 520,125 2.23% 11,947,271 USD Fulcrum Therapeutics, Inc. (FULC) 558,035 2.03% 5,502,225 USD Cogent Biosciences, Inc. (COGT) 842,048 1.97% 2,593,508 USD Qualigen Therapeutics, Inc. (QLGN) 79,209 0.35% 304,163 USD
- PEA / SRD eligible : YES / YES
-
- Compartiment A
- CAC 40 / CAC All Shares, CAC All-Tradable, CAC Large 60, Euronext 100, Euro Stoxx 50, FTSE Eurotop 100, Low Carbon 100 Europe, PEA, SBF 120, Stoxx Europe 50, STOXX Europe 600, Stoxx France 50, Stoxx Global 200
- Bloomberg Code :
SAN:FP
- Reuters Code :
SASY.PA
- Datastream Code :
F:SQ@F
Company contact information
Sanofi
54 Rue la Boétie
FR-75008 Paris
Phone : +33 (0)1 53 77 40 00
Fax : +33 (0)1 53 77 44 63
web site :
http://www.sanofi.com
Exclusive: EU eyes COVID vaccine deal with Moderna at less than $25 per dose, says source
SANOFI
Sector Pharmaceuticals - NEC
1st jan. Capitalization (M$)
SANOFI 1.85% 127 996
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
